In focus channel feed

As fears mount over J&J and As­traZeneca, No­vavax en­ters a shaky spot­light

9 months ago
Coronavirus

Near­ly a year af­ter Au­den­tes' gene ther­a­py deaths, the tri­al con­tin­ues. What hap­pened re­mains a mys­tery

9 months ago
Cell/Gene Tx

'Part of re­cov­ery is aware­ness': Pan­dem­ic casts harsh spot­light on in­dus­try-wide lack of di­ver­si­ty in clin­i­cal tri­als

9 months ago
R&D

David Liu has a new big idea: pro­teome edit­ing. It could one day shred tau, RAS and some of the worst dis­ease-caus­ing pro­teins

10 months ago
Discovery

Bio­phar­ma's suc­cess rate in bring­ing drugs to mar­ket has long been abysmal. Can new tools help rewrite that trou­bled past?

10 months ago

Ex­clu­sive: Af­ter four decades, one re­searcher's rad­i­cal HIV cure fi­nal­ly gets its shot

11 months ago
People
Startups

Af­ter 3 deaths rock the field, gene ther­a­py re­searchers con­tem­plate AAV's fu­ture

11 months ago

Can a new CRISPR tech­nique un­lock the se­crets of how can­cer spreads?

11 months ago
Discovery

They thought their gene ther­a­py failed. In­stead, it spawned a med­ical mys­tery

Last year
Discovery

As the cur­tain clos­es on the Trump pres­i­den­cy, biotech wres­tles with its fu­ture in a di­vid­ed Amer­i­ca

Last year
People

Can a dark­horse syn­thet­ic bi­ol­o­gy Covid-19 vac­cine one-up the fron­tun­ners? The Gates Foun­da­tion, Am­gen bet 'yes'

Last year
R&D
Coronavirus

Af­ter falling be­hind the lead­ers, dissed by some ex­perts, biotech show­man Patrick Soon-Sh­iong fi­nal­ly gets his Covid-19 vac­cine ready for a tri­al. But can it live up to the hype?

Last year
People
Coronavirus

End­points News ranks the top 57 play­ers in the Covid-19 vac­cine race. Here's how it stacks up to­day

Last year
Coronavirus

Af­ter Big Phar­ma aban­doned in­fec­tious dis­eases, 5 biotech con­trar­i­ans de­cid­ed to go all in. Then Covid-19 changed every­thing

Last year
People
Coronavirus

Af­ter psilo­cy­bin and ke­t­a­mine, a new biotech comes along de­vel­op­ing a drug Scott Got­tlieb fought

Last year
Startups
R&D

Chi­nese vac­cine de­vel­op­ers have be­gun to shed some se­cre­cy around Covid-19 can­di­dates. What do we know?

Last year
China
Coronavirus

Why Mer­ck wait­ed, and what they now bring to the Covid-19 fight

Last year
People
R&D

Al­ny­lam, Sarep­ta jump in­to Covid-19 game, as pan­dem­ic rekin­dles an­tivi­ral hopes of RNA-tar­get­ing tech­nol­o­gy

Last year
R&D
Coronavirus

Bank­ing on hope, swayed by hype? Hy­drox­y­chloro­quine in the time of Covid-19

Last year
FDA+
Coronavirus

Cre­ative or un­eth­i­cal? Re­searchers’ Covid-19 Go­FundMe cam­paign spurs crit­ics

Last year
R&D
Coronavirus

Nat­ur­al killers are com­ing for Covid-19 and the ther­a­py, ex­perts say, could make things worse

Last year
R&D
Coronavirus

‘If grippe con­demns, the sec­ondary in­fec­tions ex­e­cute’: What the coro­n­avirus pan­dem­ic means for the field of an­tibi­otics

Last year
Coronavirus

In­vest­ing in the time of coro­n­avirus: the good, the bad and the hope­ful, as biotech VC firms close funds worth $3B

Last year
Financing

‘It’s like the tor­toise and the hare’: A pan­dem­ic puts Sanofi’s $600M bet to the test

Last year
R&D
Coronavirus
First page Previous page 123 Next page Last page